Puma Biotechnology (PBYI) Net Cash Flow (2011 - 2026)
Puma Biotechnology's (PBYI) quarterly Net Cash Flow came in at $6.6 million in Q1 2026, up 205.96% YoY from $2.1 million in Q1 2025, and up 127.45% on a QoQ basis from -$23.9 million in Q4 2025.
Puma Biotechnology (PBYI) Net Cash Flow (2011 - 2026) Analysis & Trends
Puma Biotechnology (PBYI) has 16 years of Net Cash Flow data on file, last reported at $6.6 million in Q1 2026.
- Quarterly Net Cash Flow rose 205.96% year-over-year to $6.6 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was -$26.8 million (down 95.59% YoY) and the FY2025 annual result came in at -$39.6 million, down 157.61% from the prior year.
- Net Cash Flow advanced to $6.6 million in Q1 2026, from -$23.9 million in the prior quarter.
- In the past five years, Net Cash Flow ranged from a high of $25.2 million in Q3 2022 to a low of -$23.9 million in Q4 2025.
- A 5-year average of -$2.2 million and a median of -$1.8 million in 2022 frame the typical range for Net Cash Flow.
- Annual changes were most pronounced in 2023 — Net Cash Flow surged 229.9% — and 2025, when it sank 1321.37%.
- Tracing PBYI's Net Cash Flow over 5 years: stood at -$1.8 million in 2022, then surged by 229.9% to $2.3 million in 2023, then slipped by 14.4% to $2.0 million in 2024, then slumped by 1321.37% to -$23.9 million in 2025, then jumped by 127.45% to $6.6 million in 2026.
- The last three Net Cash Flow figures came in at $6.6 million (Q1 2026), -$23.9 million (Q4 2025), and -$1.1 million (Q3 2025), per Business Quant data.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Net Cash Flow (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn | 652.90 Mn |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn | -504.30 Mn |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn | - |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - | 374.50 Mn |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn | 407.41 Mn |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn | 17.81 Mn |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - | 225.59 Mn |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn | -496,000.00 |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn | -37.14 Mn |
| 10 | Puma Biotechnology | 451.24 Mn | 357.33 Mn | 44.03 Mn | -1.75 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | -1.75 Mn |
| Jun 30, 2026 | -1.75 Mn |
| Mar 31, 2026 | 6.56 Mn |
| Mar 31, 2026 | 6.56 Mn |
| Dec 31, 2025 | -23.89 Mn |
| Dec 31, 2025 | -23.89 Mn |
| Sep 30, 2025 | -1.14 Mn |
| Sep 30, 2025 | -1.14 Mn |
| Jun 30, 2025 | -8.37 Mn |
| Jun 30, 2025 | -8.37 Mn |
| Mar 31, 2025 | -6.19 Mn |
| Mar 31, 2025 | -6.19 Mn |
| Dec 31, 2024 | 1.96 Mn |
| Dec 31, 2024 | 1.96 Mn |
| Sep 30, 2024 | 114,000.00 |
| Sep 30, 2024 | 114,000.00 |
| Jun 30, 2024 | -9.60 Mn |
| Jun 30, 2024 | -9.60 Mn |
| Mar 31, 2024 | -7.83 Mn |
| Mar 31, 2024 | -7.83 Mn |